tirzepatide weight loss weston FDA Grants a New Indication for Obesity Management Tirzepatide for Medical Weight Loss

What the Evidence Does Not Say The evidence does not currently prove: that semaglutide is always harder on muscle than tirzepatide that tirzepatide is always harder on muscle than semaglutide that everyone on either drug will experience clinically meaningful weakness or muscle loss that medication choice alone determines the quality of the body-composition outcome This is important because readers often want a clean winner and loser

Presented for research literature review only Cassone VM et al

Conclusion The study suggests that once-daily oral elecoglipron produced clinically meaningful and progressive weight loss in adults living with obesity or overweight without diabetes